Variant Creutzfeldt-Jakob disease.
Variant CJD is a novel human prion disease that represents the first known occasion in which animal prion diseases have been transmitted to humans. There are many uncertainties concerning vCJD, including the mechanism of transmission between species, the extent of human exposure to the BSE agent, the infectious dose for humans, and the future burden of human disease. It is hoped that continuing scientific research may lead to answers to some of these questions and that further understanding of the mechanism of prion replication may lead to the development of effective treatment. Indeed a recent publication has suggested that the drugs quinacrine or chloropromazine may be candidates for the treatment of human prion diseases [42].
Ward
H J T
HJ
National Creutzfeldt-Jakob Disease Surveillance Unit, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK.
Head
M W
MW
Will
R G
RG
Ironside
J W
JW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002540:Cerebral Cortex / Q000473:pathology; D002648:Child; D007562:Creutzfeldt-Jakob Syndrome / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology